Physician Assistant Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kelli Cash

Physician Assistant, Medical Staunton, VA Physician Assistant

NPI 1023595154 CMS profile 5622094

25 Myers Corner Dr, Staunton, VA 24401

Open in the dashboard

General payments

$12,017

791 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelli Cash of Staunton, VA is reported in the CMS Open Payments database as having received $12,017 across 791 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,782 242
2024 General $3,038 199
2023 General $2,723 187
2022 General $1,398 96
2021 General $1,062 66
2019 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelli Cash
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kelli Cash were reported at $3,782. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kelli Cash Physician Assistant, Medical median Middle half National median
2019 $12 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,062 $156 $41–$563 $132
2022 $1,398 $185 $55–$649 $149
2023 $2,723 $199 $58–$717 $160
2024 $3,038 $206 $62–$740 $164
2025 $3,782 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,155 132 payments
  2. Otsuka America Pharmaceutical, Inc. $1,188 90 payments
  3. ITI, Inc. $1,153 110 payments
  4. Alkermes, Inc. $1,010 66 payments
  5. Lundbeck LLC $802 62 payments
  6. Neurocrine Biosciences, Inc. $770 39 payments
  7. Janssen Pharmaceuticals, Inc $647 32 payments
  8. E.R. Squibb & Sons, L.L.C. $432 20 payments
  9. Vanda Pharmaceuticals Inc. $418 19 payments
  10. Teva Pharmaceuticals USA, Inc. $360 25 payments
  11. Other $3,082 196 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,017 791 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $1,067 59 payments
  2. REXULTI $874 72 payments
  3. LYBALVI $851 58 payments
  4. INGREZZA $770 39 payments
  5. ABILIFY MAINTENA $721 47 payments
  6. CAPLYTA $677 58 payments
  7. ARISTADA Cns $668 46 payments
  8. ARISTADA Cns $668 46 payments
  9. ARISTADA Cns $593 42 payments
  10. ARISTADA Cns $593 42 payments
  11. Other $9,728 632 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

2,330

Median for Physician Assistant: 241

Drug cost

$216,796

Median for Physician Assistant: $4,110

Branded share of claims

20%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 52 $81,185
Abilify Maintena Aripiprazole Brand 17 $47,264
Rexulti Brexpiprazole Brand 15 $37,589
Entresto Sacubitril/Valsartan Brand 11 $7,271
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 70 $5,868
Lurasidone Hcl Generic 21 $4,120
Duloxetine Hcl Generic 127 $2,957
Oxcarbazepine Generic 45 $2,891
Quetiapine Fumarate Generic 83 $2,000
Atomoxetine Hcl Generic 16 $1,942

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$13,670

Medicare's payments for the services billed

Medicare patients

75

Average age 72

Services billed

411

50 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 32%
Arthritis 31%
Chronic kidney disease 24%
Osteoporosis 23%
Depression 20%
Ischemic heart disease 15%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$560 52 —
REXULTI
$483 15 —
CAPLYTA
$403 — —
INGREZZA
$216 — —
Azstarys
$152 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

791 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record